Dr. Novack published three recent key articles in leading ophthalmology journals. These are:
-How FDA views post-hoc analyses (moving the target after the arrow has been shot): Novack GD. The importance of a priori statistical planning in controlled clinical trials. Am J Ophthalmology 2015;160(1):4-5.
-Patient payments for prescription medications (Novack GD. What determines how much your patient pays for their medication in the United States? Am J Ophthalmol 2016;167(48-51).
View all articles by Gary D. Novack on the American Journal of Opthamology website.
-A “unified field theory” of treatment adherence and performance (Novack GD. Time to take your medicines, seriously. Ocul Surf 2016;14(3):410-415.)
View all articles by Gary D. Novack on the Ocular Surface Journal website.
Together, these articles provide insight on the unique perspective of Dr. Novack on drug development.
Also recently published was an overall review of ocular pharmacology (Novack GD, Robin AL. Ocular Pharmacology. J Clin Pharmacol 206: 56(5): 517-527. (ISSN)1552-4604, and an updated review of the utility of cannabinoids in the treatment of glaucoma (Novack GD. Cannabinoids for treatment of glaucoma. Curr Opin Ophthalmology 27(2): 146-150).
A complete list of Dr. Novack’s over 240 publications may be found at https://www.pharmalogic.com/publications/